VERAXA Biotech (NASDAQ: VRXA) is expanding its use of human-relevant testing methods across its oncology research programs, a strategic shift that could improve the predictive value of preclinical data and reduce reliance on animal models in cancer drug development. The Switzerland-based company, with a key financial and regulatory presence in the U.S., outlined its implementation of New Approach Methodologies (NAMs) in an October 7, 2026, announcement. NAMs encompass non-animal techniques such as cell-based assays and computational modeling, and VERAXA is aligning them with U.S. Food and Drug Administration guidance.
The importance of this move lies in its potential to address a longstanding challenge in oncology drug development: the frequent disconnect between animal study results and human clinical outcomes. By adopting NAMs, VERAXA aims to generate data that better reflect human biology, which could lead to more informed decisions as it advances its pipeline of BiTAC(R) T-cell engagers, BiTAC-based antibody-drug conjugates, and bispecific antibody-drug conjugates for cancer treatment. The company reported that new three-dimensional spheroid data reinforce the ability of its models to assess the dual-target specificity of its lead T-cell engager candidates, a critical feature for therapies designed to engage two targets simultaneously.
A key implication of the strategy is the reduction in animal use. An ex vivo study involving 10 low-passage patient-derived xenograft models of non-small cell lung cancer required about 10 mice, compared with an estimated 200 or more for comparable in vivo efficacy studies. VERAXA said its lead BiTAC candidate induced potent T-cell-mediated tumor-cell killing across the tested models, while relevant controls showed minimal activity. If such human-relevant models prove consistently predictive, they could accelerate preclinical timelines and lower development costs, while also addressing growing regulatory and ethical pressure to minimize animal testing.
The announcement positions VERAXA among biotechnology companies increasingly turning to NAMs as the FDA and other regulators signal greater openness to alternative methods. For investors, the strategy may enhance the credibility of the company’s preclinical package and its potential to translate findings into human trials more efficiently. More details on the company’s approach are available through the full announcement, and ongoing updates can be found in the company’s newsroom at https://ibn.fm/VRXA. The original release was distributed via www.newmediawire.com.
As VERAXA continues to develop its antibody-based cancer therapies, the adoption of human-relevant testing represents a bet that better preclinical models will translate into higher probabilities of clinical success. The company’s ability to validate its NAMs across additional programs and ultimately demonstrate improved predictiveness will be closely watched by investors and regulators alike.
